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Abstract 
 
Introduction: Furosemide is a potent loop diuretic commonly and variably used by 
neonatologists to improve oxygenation and lung compliance in premature infants despite its lack 
of Food and Drug Administration approval for use in premature infants.  It lacks FDA approval 
because of safety concerns, specifically the risk of hearing loss and 
nephrocalcinosis/nephrolithiasis (NC/NL). I conducted a systematic review of all trials and 
observational studies examining the association of these safety outcomes with exposure to 
furosemide in premature infants.   
Methods: I searched MEDLINE, EMBASE, and clinicaltrials.gov.  Included studies reported on 
the outcomes of sensorineural hearing loss or NC/NL in premature infants (< 37 weeks 
completed gestational age) who received at least one dose of enteral or intravenous 
furosemide. I abstracted all selected studies and assessed quality based on the Cochrane 
Collaboration’s tool for randomized trials and the ROBINS-1 tool for observational studies. I 
assigned a grade for the strength of evidence for each key question using guidelines developed 
by the Evidence-based Practice Center program of the U.S.  Agency for Healthcare Research 
and Quality. 
Results: I identified 390 titles, 165 of which met criteria for a full-text review. Thirty studies met 
full inclusion criteria for the review, including 11 studies examining hearing loss and 19 studies 
examining NC/NL. Only one randomized controlled trial was included in this review. I found 
mixed results for the association of hearing loss and NC/NL with furosemide exposure, with 
varying quality of studies. I determined the strength of evidence for both outcomes to be low. 
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The most common limitation in these studies was the lack of control for confounding factors 
which are independently associated with the outcomes of interest. 
Conclusions: The evidence for the risk of hearing loss and NC/NL in premature infants exposed 
to furosemide is low. Further randomized controlled trials of furosemide in premature infants are 
urgently needed to adequately assess the risk of hearing loss and NC/NL, provide evidence for 
improved FDA labeling, and promote safer prescription practices.  
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Introduction 
 
Furosemide is a potent diuretic that acts in the proximal and distal tubules, as well as the 
loop of Henle, to inhibit sodium and chloride reabsorption in the kidneys. The use of diuretics 
such as furosemide may alleviate symptoms associated with volume overload, including 
pulmonary edema. In the premature infant population, early pulmonary edema and excessive 
intravenous fluid administration are associated with an increased risk of bronchopulmonary 
dysplasia (BPD), also called chronic lung disease of prematurity.1, 2 Therefore, furosemide may 
be part of a clinical approach to reducing the risk of BPD in premature infants.  
Despite the proposed benefits and biological plausibility of using furosemide to improve 
respiratory outcomes, the efficacy of furosemide in premature infants has not been established. 
A Cochrane systematic review examining loop diuretics for preterm infants found no evidence to 
support an improvement in long-term outcomes, including BPD.3  However, results from the 
review indicated that chronic administration of furosemide (i.e., at least 7 days) improves 
oxygenation and lung compliance in premature infants with established BPD. The review 
emphasizes the need for randomized clinical trials to assess the effects of furosemide 
administration on morbidity and mortality.  
Notwithstanding the absence of data supporting the efficacy of furosemide, the 
medication is commonly used by clinicians in the neonatal intensive care unit (NICU) with the 
intention to improve oxygenation and wean respiratory support in premature infants.  A cohort 
study from more than 300 NICUs in the U.S. found that furosemide was the fifth most common 
drug used between the years 2005 to 2010 in premature infants with birth weights less than 
1000 grams, with approximately 50% of these infants exposed to at least one dose of 
furosemide during their initial hospitalization.4 Although other diuretic medications are used in 
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the NICU for similar indications, furosemide is by far the most commonly used diuretic in the 
NICU, accounting for 93% of diuretic use.5 Furosemide is also variably used in the NICU setting.  
A cohort study of infants with birth weights less than 1500 grams from more than 200 U.S. 
NICUs over a 15 year period found considerable variability in the percentage of infants exposed 
to at least one dose of furosemide at each particular site, with a median exposure by site of 33% 
and a range of 0 to 75%.  The observations from this study emphasize the lack of a universally 
accepted standard governing when to expose an infant in the NICU to furosemide and indicate 
that at some centers, no exposure to furosemide is an option.5  
 In addition to uncertainty about efficacy, concerns about the safety of furosemide in 
premature infants persists.  The Food and Drug Administration (FDA) has approved furosemide 
for the treatment of edema associated with congestive heart failure, cirrhosis, and nephrotic 
syndrome in children and adults.  Furosemide is not approved by the FDA for use in premature 
infants and, as a result, any use in this population is considered off-label. Specifically, the FDA 
label for furosemide includes a warning that infants less than 31 weeks post-conceptual age 
(i.e., post-menstrual age) receiving doses exceeding 1 mg/kg/day intravenously may develop 
plasma levels resulting in ototoxicity.  The label also notes that renal function monitoring and 
renal sonography should be considered in premature infants, as furosemide may precipitate 
nephrocalcinosis.   
 The primary safety concern about the use of furosemide in premature infants is 
ototoxicity, or hearing loss. The incidence of sensorineural hearing loss is approximately 0.7-
1.5% in neonates admitted to the NICU and it is more common in infants born prematurely.6, 7  
The association of hearing loss and furosemide relies heavily on studies conducted in adults 
receiving high doses of the medication. In one study, reversible hearing loss occurred in 50% of 
adult patients with uremia given a single intravenous 1000 mg dose of furosemide, which is 50 
times the usual adult dose.8 A case series reported transient deafness in 3 adult patients with 
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renal impairment given intravenous doses of 2000-3000 mg.9 Finally, a trial of 19 adult patients 
receiving furosemide or placebo resulted in one patient with permanent deafness who had 
received 14 days of 1000 mg per day. The authors of the trial reported that furosemide levels in 
excess of 100 mcg/mL were associated with ototoxicity.10 The proposed mechanisms for 
furosemide-induced ototoxicity include changes in potassium concentrations in the cochlear 
endolymph and impairment of cellular proliferation.11, 12 
 Furosemide use in premature infants has also been implicated in the development of 
nephrocalcinosis and nephrolithiasis, or renal calcifications and stones, although the etiology in 
this population is likely to be multifactorial.13, 14 Nephrocalcinosis is diagnosed by renal 
ultrasonography and has the appearance of increased echogenicity in the medullary pyramids 
of the kidney. Renal calculi, or nephrolithiasis, are detected on ultrasound by echogenic foci in 
the calyces or renal pelvis.  Loop diuretics, such as furosemide, reduce renal tubular 
reabsorption of calcium resulting in hypercalciuria, which is the proposed mechanism for its 
association with nephrocalcinosis.  However, this association is often confounded by 
concomitant exposure to other therapies, such as dexamethasone, long-term parenteral 
nutrition, and mechanical ventilation, which have been identified as risk factors for renal 
calcifications.15, 16 
 Existing safety data on the use of furosemide in adults and children cannot be 
extrapolated to premature infants due to higher extracellular fluid volume per unit body weight, 
immature hepatic and renal function, and a more permeable blood-brain barrier in premature 
infants, variables which can alter the rates of drug absorption, distribution, metabolism, and 
elimination. 17 Four studies of furosemide pharmacokinetics in premature infants demonstrate 
significant variability in the volume of distribution, clearance, and half-life of the drug based on 
gestational age at birth, birth weight, and postnatal age.18-21  The limited available data on 
pharmacokinetics and safety have led to a growing recognition of the need for clinical trials in 
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premature infants to determine the safety and efficacy of therapeutic agents, such as 
furosemide.22, 23   
 In the absence of robust data from clinical trials, the best available method for evaluating 
the safety of furosemide in premature infants includes a thorough review of the limited number 
of randomized control trials, as well as non-controlled studies such as cohort and case-control 
studies. This systematic review will synthesize all trials and observational studies in which 
premature infants were exposed to at least one dose of furosemide and report on the following 
outcomes: hearing loss and nephrocalcinosis/nephrolithiasis.  This review differs from Cochrane 
reviews in its inclusion of observational studies, which comprise the majority of available 
evidence for furosemide safety in premature infants. The key questions this systematic review 
will address are the following: 
Key Question 1: Does exposure to furosemide in premature infants increase the risk of hearing 
loss? 
Key Question 2: Does exposure to furosemide in premature infants increase the risk of 
nephrocalcinosis/nephrolithiasis? 
Methods 
 I developed a protocol to determine study eligibility criteria.  Any observational cohort 
study or clinical trial in which premature infants (< 37 weeks completed gestational age) were 
exposed to at least one dose of furosemide while hospitalized in the NICU was eligible for 
review.  Comparators used were premature infants without exposure to furosemide, when 
available. The outcomes of interest were hearing loss and nephrocalcinosis/nephrolithiasis.  
Table 1 displays the eligibility criteria for this systematic review.  
 I searched the following databases for the relevant literature: MEDLINE and EMBASE. I 
searched clinicaltrials.gov to include results of unpublished studies. The references of relevant 
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articles within this search were reviewed by the investigator for additional articles of interest.  
The date of the most recent search was February 3, 2018.  
The MEDLINE search used the following Medical Subject Heading terms: “furosemide” AND 
“infant, premature.” The final search including the following string of search terms: 
"furosemide"[MeSH Terms] OR "furosemide"[All Fields] AND "infant, premature"[MeSH Terms] 
OR ("infant"[All Fields] AND "premature"[All Fields]) OR "premature infant"[All Fields] OR 
"preterm"[All Fields] AND "infant"[All Fields] OR "preterm infant"[All Fields] OR "neonate"[All 
Fields]. The EMBASE search used the following terms: ('premature infant'/exp OR 'premature 
infant' OR (('premature'/exp OR premature) AND ('infant'/exp OR infant))) AND 
('furosemide'/exp OR furosemide). The clinicaltrials.gov search used the terms “premature 
infant” and “furosemide.”  
 All studies resulting from the preceding search strategy were compiled and duplicates 
were removed. I reviewed titles and abstracts for relevance using the software program 
Abstrackr.24  Full text articles were then screened for eligibility criteria by asking the following 
questions in order, with the determination of ineligibility of the study if any of the answers were 
negative: “Was the study originally published in English? Did the study use human participants? 
Does the study include premature infants (born less than 37 weeks gestational age) who were 
exposed to at least one dose of furosemide (enteral or intravenous)? Does the study examine 
the risk of hearing loss, nephrocalcinosis, or nephrolithiasis in premature infants exposed to at 
least one dose of furosemide?” Data abstraction forms were developed with these questions 
included for the reviewer to determine eligibility of the study and, if eligibility criteria met, to 
record the study design, population characteristics, characteristics of comparison group, 
outcomes examined, sample size, duration of follow-up, and funding sources. These data 
abstraction forms were used by the investigator to report on the results (Appendix).  
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 I assessed the quality (internal validity) of randomized controlled trials using the 
Cochrane Collaboration’s tool for assessing risk of bias in clinical trials.25 This tool includes the 
assessment of randomization procedures, allocation concealment, blinding of participants and 
investigators, completeness of outcomes data, selective reporting, and the risk of other biases. 
Each randomized controlled trial included in the systematic review was graded on each of these 
parameters as high risk of bias, low risk of bias, or unclear risk of bias.  I assessed the risk of 
bias in non-randomized studies using the ROBINS-1 tool, which assesses confounding biases, 
bias in the selection of participants, classification biases, biases due to deviations from intended 
interventions, missing data biases, and biases in measurement of outcomes.26  Bias is rated on 
a scale of low, moderate, serious, or critical risk of bias, or no information.  I then graded the 
strength of the evidence for each key question using guidance from the Evidence-based 
Practice Center program of the U.S. Agency for Healthcare Research and Quality.27 
 The pre-specified outcome measures were odds ratios and risk ratios, where 
appropriate, with 95% confidence intervals for the exposure of furosemide in premature infants 
with each of the outcomes of interest addressed in the key questions. Results of each study 
were described and only the information pertaining to the outcomes of interest in the key 
questions were included.  
Results 
 I identified 260 records through MEDLINE, 139 records through EMBASE, and 1 study 
from clinicaltrials.gov.  After duplicates were removed, 390 records were left. Of the 390 records 
screened for eligibility, 224 records were excluded due to study design, non-human population, 
or non-English language. The full text of the remaining 165 articles was reviewed and 140 
articles were excluded for inappropriate study population or lack of relevant safety outcome. 
Five articles found in the reference lists of reviewed articles met the eligibility criteria and were 
included.  These studies did not appear in the original search due to the use of a variation in the 
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drug name: “frusemide”, instead of “furosemide.”  In total, 30 articles were included in the 
quantitative analysis. See Figure for the PRISMA flow diagram.    
Key Question 1: Does exposure to furosemide in premature infants increase the risk of 
hearing loss? 
 Only one randomized controlled trial of furosemide compared to placebo in premature 
infants reported on the outcome of hearing loss.28  In this trial, 24 premature infants were 
randomized to receive either furosemide or placebo for 7 days.  The initial dose of furosemide (1 
mg/kg IV or 2 mg/kg orally every 12 hours) was doubled after 48 hours if there was not a 50% 
increase in urine output over 12 hours.  In the 17 patients available for analysis (7 infants in 
treatment group and 10 infants in the control group), no hearing loss was detected prior to 
discharge.  
 I identified 10 observational studies examining the association of furosemide and 
hearing loss in preterm infants: 4 retrospective cohort studies and 6 case-control studies.29-38  
The results of the studies were mixed; however, an association between furosemide and 
neonatal hearing loss was found in seven of the ten observational studies.29-32, 34, 36, 38 Two 
cohort studies and one case-control study did not find an association with furosemide and 
hearing loss.33, 35, 37 These negative studies were conducted in single centers and did not 
consider dose exposure of furosemide.  
 Table 2 summarizes the population characteristics, sample size, outcome measures, 
and results from each study.  The studies varied considerably in their definitions of hearing loss, 
including the type of auditory testing used and length of follow-up.  However, every study 
included a hearing screen in all participants prior to NICU discharge and every infant classified 
as having hearing loss failed the initial newborn hearing screen.  Auditory testing in these 
studies included either auditory brain stem response (ABR)29, 31, 37, brainstem auditory evoked 
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response (BAER)30, otoacoustic emission (OAE) test32, behavioral audiometry in older children, 
or some combination of these tests33-36, 38.  Several studies differentiated auditory neuropathy or 
auditory neuropathy spectrum disorders, in which there is a defect in the transmission of sound 
from the inner hair cells of the cochlea to the brain via the auditory nerve, from the broader 
category of sensorineural hearing loss (SNHL).34-36 Children with auditory neuropathy have an 
abnormal ABR with preserved OAE testing, while those with SNHL have abnormal results on 
both tests.   
 Although a majority of the studies did not consider dosing, three studies described the 
dose and duration of furosemide and its association with hearing loss and each of these studies 
found a positive association between furosemide and hearing loss.29, 31, 36  Salamy, et al. found 
higher cumulative dose exposure of furosemide in infants with hearing loss than was true in 
infants without hearing loss (mean +/- standard deviation: 139.1 +/- 130 mg/kg vs. 41.5 +/- 76 
mg/kg; p < 0.001), in addition to longer duration of furosemide use in the hearing loss group 
(52.5 +/- 43 days vs. 19 +/- 23 days; p < 0.001).29 Borradori, et al. described higher maximum 
daily dose of furosemide (3.2 +/- 0.58 mg/kg vs. 2.45 +/- 0.79 mg/kg; p = 0.05), longer duration 
of treatment (17 +/- 8.3 days vs. 3.4 +/- 2.1 days; p < 0.001), and higher cumulative dose 
exposures (26.9 +/- 13.7 mg/kg vs. 6.17 +/- 4 mg/kg; p < 0.001) in infants with hearing loss than 
in infants with normal hearing.31 Finally, Martinez-Cruz, et al. reported a longer duration of 
furosemide treatment in infants with hearing loss compared to those with normal hearing (17.5 
+/- 10 days vs. 7 +/- 4.9 days; p = 0.002).  
 I assessed the quality of each study based on the risk of bias in the seven domains of 
the ROBINS-I tool for non-randomized studies (Table 3).  The risk of bias in the McCann study 
is included in Table 4 using the Cochrane Risk of Bias Tool. The primary determining factor for 
the assessment of moderate or serious risk of bias was whether an appropriate analysis method 
was used that controlled for important perinatal factors, such as severity of illness, duration of 
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hospitalization, birth weight, gestational age, and co-morbidities known to be risk factors for 
hearing loss. I considered one study to have a critical risk of bias due to grouping furosemide 
exposure with other medications as a single variable termed “ototoxins”.38  There was no pattern 
relating quality to the results of the studies (i.e., both positive and negative studies included a 
mix of moderate and serious risks of bias).   
 I determined that the strength of evidence for the association of hearing loss and 
furosemide exposure in premature infants is low based on my review of the existing literature.  
This judgement is based on the high risk of bias in the observational studies, which often did not 
adequately account for the severity of illness in infants exposed to furosemide, and the 
inconsistency in the results. Furthermore, there is a problem with the directness of comparisons 
as infants exposed to furosemide are also more likely to receive additional interventions which 
may increase the risk of hearing loss, such as concomitant ototoxic medications and mechanical 
ventilation. According to the Agency for Healthcare Research and Quality (AHRQ), a low grade 
indicates “low confidence that the evidence reflects the true effect [and] further research is likely 
to change the confidence in the estimate of effect and is likely to change the estimate.”27 It is 
clear that further clinical trials are needed to adequately assess the risk of hearing loss in 
premature infants exposed to furosemide.   
Key Question 2: Does exposure to furosemide in premature infants increase the risk of 
nephrocalcinosis/nephrolithiasis? 
 No randomized controlled trials of furosemide in premature infants have been performed 
that include outcome data on the incidence of nephrocalcinosis.  I identified 19 cohort studies 
examining the association of furosemide exposure and nephrocalcinosis/nephrolithiasis 
(NC/NL).39-57 The results of the studies were mixed; however, 11 of the 19 studies found an 
association between furosemide and NC/NL.39-41, 43-45, 48, 49, 52, 54, 55, 57 All studies were performed 
at single centers, except Schell-Feith, et al.., which included patients from two centers. Three of 
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the studies resembled case series in that there was no inclusion of adequate control groups 
without NC: one of these studies found an association of furosemide with NC and two studies 
did not.39, 46, 50   
Table 5 summarizes the population characteristics, sample size, outcome measures, 
and results from each study.  There was considerable variability in the inclusion criteria, the 
timing of renal ultrasonography, and duration of long-term follow-up. However, all of the 
reviewed studies included premature infants with sonographic evidence of NC/NL prior to 
discharge from the NICU.  Of the studies that included subsequent ultrasounds after NICU 
discharge, complete resolution of NC occurred in 44-100% of patients by 2 years of age.40, 42, 44-
47, 50, 54-57  However, these data on outcomes are incomplete, as they do not include infants with 
the most severe disease, who expired during their NICU hospitalization, and infants lost to 
follow-up after discharge.  
A dose-response relationship between furosemide and NC/NL was evaluated in 8 
studies.42, 43, 46, 47, 49, 50, 52, 54 Half of these studies found no association between dose and the 
development of NC/NL. Ezzedeen, et al. found no difference in average daily dose or duration 
of furosemide between 17 premature infants with NC and 3 infants without NC, all of whom 
were exposed to furosemide while in the NICU.42 Short, et al. also found no difference in mean 
dose of furosemide before detection of NC on renal ultrasound compared to infants without 
NC.43  The study by Pope, et al. did not detect a difference in cumulative dose or duration of 
treatment between infants with resolution of NC compared to those with persistent findings of 
NC and Narendra, et al. found no difference in median total dose of furosemide before detection 
of NC and in those infants without NC.46, 49 In contrast, Hoppe, et al. found that infants with 
resolution of NC received lower daily dosages of furosemide than did those with persistent NC ( 
p < 0.05) and Saarela, et al. determined that mean cumulative doses of furosemide were 
significantly higher in infants with NC than in those without NC (18.8 mg vs 5.0 mg; p : 0.001).47, 
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50 In a single center study, Ketkeaw, et al. found  higher cumulative doses of furosemide in 
infants with development of NC than in those without NC (mean +/- standard deviation: 102.2 
+/- 118.2 mg vs 32.3 +/- 81.1 mg; p = 0.001).52 Gimpel, et al. identified exposure to furosemide 
with cumulative dose > 10 mg/kg was the strongest independent risk factor for NC in a 
multivariate analysis of premature infants (OR 48.1 (95% CI 4.0-585); p < 0.01).54 
 I assessed the quality of each study based on the risk of bias in the seven domains of 
the ROBINS-I tool for non-randomized studies (Table 6).   I determined that one study had a 
critical risk of bias and resembled a case series in its lack of the use of a control group.39 The 
most common reason I considered a study to have a serious risk of bias was the absence of 
adjustment for severity of illness.  Three studies used multivariate analysis to control for the high 
correlation of cumulative furosemide exposure with birthweight, duration of mechanical 
ventilation, and severity of BPD, all variables that are independently associated with the 
development of NC/NL. 43, 49,54  One study found that furosemide exposure was the strongest 
independent risk factor for NC, despite controlling for multiple markers of illness severity. 
However, two studies that considered the temporal relationship between furosemide and NC 
found no difference in mean dose of furosemide before detection of NC on renal ultrasound in 
infants who did or did not subsequently develop NC.43, 49 There was no pattern relating quality to 
the results of the studies (i.e., both positive and negative studies included a mix of moderate 
and serious risks of bias).   
 I determined that the strength of evidence for the association of NC/NL and furosemide 
exposure in premature infants is low based on our review of the existing literature.  No clinical 
trials of furosemide have examined the outcome of NC/NL. There is a high risk of bias in the 
numerous observational studies reviewed as only a few studies accounted for other renal stone-
promoting factors, such as excessive calcium, phosphorus, and vitamin D intake. The AHRQ 
classifies evidence as indirect if “it uses intermediate or surrogate outcomes instead of ultimate 
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health outcomes; one body of evidence links the intervention to intermediate outcomes and 
another body of evidence links the intermediate to most important (health or ultimate) 
outcomes.” (p. 515) The endpoint of NC/NL is likely a surrogate outcome for chronic kidney 
disease and cardiovascular disease, which were detected in a minority of patients included in 
the studies. Although clinical trials are needed to determine the relationship of furosemide and 
NC/NL, adequate long-term follow-up will also be required to determine any lasting effects of 
NC/NL on renal and cardiovascular health.  
Discussion 
I found mixed evidence that furosemide exposure increases the risk of hearing loss or 
NC/NL in premature infants. I determined that the strength of evidence for the association of 
these outcomes with furosemide exposure is low. With the exception of one randomized 
controlled trial including hearing loss as an outcome, all reviewed studies were cohort studies. 
These studies’ observational designs left many important potential confounding variables not 
well-accounted for.  Some of the included cohort studies were of high quality and used 
multivariable analyses to account for confounding, but randomized controlled trials of 
furosemide are urgently needed to assess the risks of hearing loss and nephrocalcinosis in 
premature infants.  
Additional potential adverse outcomes of furosemide use in premature infants include 
metabolic bone disease (osteopenia) of prematurity and electrolyte abnormalities related to 
urinary loss of sodium, chloride, and calcium.58-60  As with other adverse outcomes, the etiology 
of metabolic bone disease in premature infants likely has many causes, and infants with severe 
illness often have multiple risk factors such as insufficient phosphorus intake, vitamin D 
deficiency, prolonged immobilization, mechanical ventilation, and exposure to steroids and 
antibiotics.61-63 However, there is a lack of consensus on the definition of metabolic bone 
disease of prematurity, with some definitions relying on serum mineral levels and others based 
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on radiographical findings.64 As a result, this review did not focus on metabolic bone disease of 
prematurity as an outcome of interest in premature infants exposed to furosemide. 
A phase II clinical trial by the Pediatric Trials Network is underway to better understand 
the safety of furosemide in premature infants at risk of BPD, a.65 This trial will enroll premature 
infants born less than 29 weeks’ gestation and receiving positive airway pressure or mechanical 
ventilation on 7-28 days postnatal age.  The study design includes a dose escalation schedule 
with three cohorts randomized to placebo or furosemide. Primary outcomes will include safety 
information on hearing loss (based on BAER prior to discharge) and NC/NL determined by 
serial renal ultrasounds.  Secondary outcomes will assess effectiveness of early furosemide in 
the prevention of BPD or death.  This will be the first randomized controlled trial of furosemide in 
premature infants to measure hearing loss and nephrocalcinosis. The dose escalation design of 
the study will allow for evaluation of a dose-response relationship of furosemide and the 
outcomes of hearing loss and nephrocalcinosis. 
This systematic review was limited by the inclusion of only one randomized controlled 
trial. The remaining studies were cohort and case-control studies, which by the nature of their 
study design are unable to demonstrate a causal role. While many randomized controlled trials 
of furosemide in premature infants have been performed, very few included data on safety 
outcomes, which were the subject of this review.  In addition, the search strategy may not have 
included all available studies; for instance, I found that some studies included from our review of 
reference lists used variable spellings of “furosemide.” The field of neonatology has changed 
dramatically over the past 20 years with the introduction of antenatal steroids, surfactant 
replacement therapy, and non-invasive ventilation strategies.  These practices have resulted in 
significantly improved survival and reduced morbidities in premature infants.66, 67 Therefore, 
results from studies included in this review which were performed decades ago may not be 
applicable to infants born in the current era.  Finally, I was unable to perform a meta-analysis of 
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the included observational studies due to a lack of uniformity in outcome definitions, population 
characteristics, and length of follow-up.  
Conclusion 
 I report a systematic review of the safety of furosemide in premature infants, focusing on 
the outcomes of hearing loss and NC/NL.  Irrespective of the efficacy of furosemide in 
premature infants, the existing literature on safety outcomes depends almost entirely on 
observational data. Furthermore, few studies used analytic approaches to control for 
confounding causes of additional risk of hearing loss and NC/NL on premature infants exposed 
to furosemide. The strength of evidence for the association of hearing loss and NC/NL and 
furosemide is therefore determined to be low. Further randomized controlled trials with robust 
safety measures, such as the ongoing PTN trial, are urgently needed to assess the safety of 
furosemide in premature infants. 
Funding 
No external funding was obtained for this study.  
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Figure.  PRISMA flow diagram for inclusion and exclusion of studies68 
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Table 1: Eligibility Criteria  
Patient/Population Premature Infants ( < 37 weeks completed gestational age) 
Intervention At least one dose of furosemide (IV or PO) during hospitalization in the 
neonatal intensive care unit 
Control Premature Infants ( < 37 weeks completed gestational age) without 
exposure to furosemide 
Outcomes Hearing loss; nephrocalcinosis/nephrolithiasis 
Study Design Clinical trials, retrospective or prospective cohort studies, case-control 
studies 
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Table 2: Summary of studies examining risk of hearing loss in premature infants 
Study (Year) Design Population and 
Sample Size 
Outcome Measure Results Summary 
McCann (1985)28 Randomized controlled 
trial 
17 preterm infants with 
evidence of chronic lung 
disease (7 infants 
received furosemide and 
10 infants received 
placebo) 
Audiology screen at 
discharge and follow-
up visits 
Normal hearing in all 
infants. 
Salamy (1989)29 Cohort study 244 preterm infants (GA 
24- 34 weeks) 
Auditory brain stem 
response (ABR) in 
NICU and follow-up; 
behavioral 
audiometry from 3 
months to 4 years 
Infants with SNHL received 
greater amounts of 
furosemide for longer 
durations, in combination 
with aminoglycoside or 
vancomycin therapy (p < 
0.001 for all factors). 
Brown (1991)30 Case-control study 35 neonates with SNHL 
and 70 matched 
hearing-intact controls 
 
Brainstem auditory 
evoked response 
(BAER) testing prior 
to discharge from 
NICU 
17/35 (49%) neonates with 
SNHL and 6/70 (9%) 
controls were exposed to 
furosemide (p < 0.0001). 
Furosemide was an 
independent risk factor for 
SNHL when controlling for 
BW and GA.  
Borradori (1997)31 Case-control study 8 children with 
progressive bilateral 
deafness born preterm 
(GA ≤ 34 weeks) with 16 
controls matched on GA 
and BW and 15 controls 
matched on perinatal 
complications 
ABR at NICU 
discharge and follow-
up 
8/8 (100%) infants with 
SNHL and 13/15 (87%) 
controls matched on 
perinatal complications 
received furosemide (NS). 
Mean duration (p < 0.001), 
total cumulative dose (p 
<0.001), and maximum 
daily dose (p = 0.05) were 
higher in SNHL group. 
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Ertl (2001)32 Case-control study 22 preterm infants with 
SNHL and 25 controls 
matched on GA, BW, 
and perinatal factors 
associated with hearing 
loss 
Otoacoustic emission 
(OAE) test and ABR 
if failed OAE 
4/22 (18%) infants with 
SNHL and 1/25 (4%) 
controls received 
furosemide (p < 0.01). 
Rais-Bahrami (2004)33 Cohort study 57 neonates who 
received furosemide and 
207 neonates who did 
not receive furosemide 
with hearing screen prior 
to NICU discharge 
OAE, ABR, or both 
prior to NICU 
discharge 
No statistically significant 
difference in abnormal 
hearing screen in 
furosemide and non-
furosemide groups (15.5% 
vs. 15.9%; p = 0.95). 
Xoinis (2007)34 Case-control study 95 neonates with 
hearing loss (71 with 
SNHL and 24 with 
auditory neuropathy) 
and 95 controls matched 
on GA, BW, and birth 
year 
SNHL defined as 
abnormal ABR and 
OAE; Auditory 
neuropathy (AN) 
defined as abnormal 
ABR with preserved 
OAE  
Higher exposure to 
furosemide in SNHL group 
(50.7%) and AN group 
(95.8%) compared to 
control group (32.6%) (p 
<0.05) for both 
comparisons.  
Coenraad (2011)35 Case-control study 9 neonates with hearing 
loss (auditory 
neuropathy spectrum 
disorder- ANSD) and 36 
controls matched on GA, 
gender, and birth year  
ABR screening prior 
to NICU discharge 
and repeat ABR and 
OAE at follow-up visit 
for failed screening. 
ANSD defined as 
abnormal ABR with 
preserved OAE 
No statistically significant 
differences in furosemide 
exposure between ANSD 
group and controls (44.4% 
vs. 25%; p = 0.56).  
Martinez-Cruz (2012)36 Case-control study 6 children with SNHL 
and 87 normal-hearing 
controls with birth 
weights < 750 grams 
BAER screening and 
OAE at follow-up 
visits for failed initial 
screening 
6/6 (100%) infants with 
SNHL and 45/87 (52%) 
control infants received 
furosemide (p = 0.002). 
Longer average duration of 
furosemide in SNHL infants 
who received furosemide 
compared with controls 
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(17.5 +/- 10 days vs. 7.0 +/- 
4.9 days). 
Rastogi (2013)37 Cohort study Included all infants with 
BW  
< 1500 grams. 61 failed 
hearing screen prior to 
discharge and 283 with 
normal hearing screen 
ABR prior to NICU 
discharge; Follow-up 
at 2 years for failed 
screening to 
determine hearing 
status 
Multivariate analyses found 
no association with 
furosemide and hearing 
loss when adjusting for BW, 
GA, and other perinatal risk 
factors (OR 1.18; p = 0.3). 
Wang (2017)38 Cohort study Included all infants with 
BW ≤ 1500 grams. 297 
infants with normal 
hearing and 12 infants 
with hearing loss 
OAE before 
discharge and BAER 
at 3 months 
corrected age if failed 
initial screen 
Exposure to ototoxins 
(furosemide and/or 
gentamicin) was associated 
with hearing loss (OR 3.62; 
95% CI 1.67 – 7.82).  
 Abbreviations: GA – Gestational Age; ABR – Auditory brain stem response;  SNHL - Sensorineural hearing loss; BAER- 
Brainstem auditory evoked response; NICU - Neonatal Intensive Care Unit;  BW – Birthweight; NS – Non-significant; OAE- 
Otoacoustic emission; AN – Auditory neuropathy; ANSD – Auditory neuropathy spectrum disorder; OR – Odds ratio; CI – 
Confidence Interval. 
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Table 3: Quality assessment of observational studies examining risk of hearing loss in premature infants 
Study (Year) Risk of Bias (Low, 
Moderate, Serious, Critical, 
No Information) 
Comments 
Salamy (1989)29 Moderate Confounding well-accounted for by assessing 
“neonatal status” based on duration of hospitalization, 
days of assisted ventilation, radiography and lab 
results, etc.   
Brown (1991)30 Serious Serious risk of bias in confounding domain: Selection 
of variables included in the multivariate analyses 
based solely on results of univariate analyses and did 
not adequately account for severity of illness in each 
group. 
Borradori (1997)31 Moderate Confounding well-accounted for by the creation of two 
control groups based on BW/GA and perinatal 
complications related to risk of ototoxicity. 
Ertl (2001)32 Serious Serious risk of bias in confounding domain: infants not 
matched on severity of illness or co-morbidities 
associated with hearing loss.   
Rais-Bahrami (2004)33 Serious Serious risk of bias in confounding domain: no 
adjustment for perinatal factors related to hearing 
loss. 
Xoinis (2007)34 Serious Serious risk of bias in confounding domain: infants not 
matched on severity of illness or co-morbidities 
associated with hearing loss.   
Coenraad (2011)35 Serious Serious risk of bias in confounding domain: infants not 
matched on severity of illness or co-morbidities 
associated with hearing loss.   
Martinez-Cruz (2012)36 Serious Serious risk of bias in confounding domain: infants not 
matched on severity of illness or co-morbidities 
associated with hearing loss.   
Rastogi (2013)37 Moderate Confounding well-accounted for in multivariate 
analyses, which adjusted for GA, BW, and other 
known perinatal risk factors for hearing loss.  
29 
 
Wang (2017)38 Critical Critical risk of bias in classification of interventions 
domain: ototoxic medications grouped as one variable 
(i.e., furosemide not identified as a single risk factor).  
Abbreviations: BW – Birth weight; GA – Gestational age. 
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Table 4: Risk of bias in trials examining risk of hearing loss in premature infants 
 
 
 
Study (Year) 
Risk of Bias (High, Low, Unclear) 
 
Random 
Sequence 
Generation 
Allocation 
Concealment 
Blinding of 
Participants 
and 
Personnel 
Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome 
Data 
Selective 
Reporting 
Other Bias 
McCann 
(1985)28 
Low Low Low Low High Unclear Low 
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Table 5: Summary of studies examining risk of nephrocalcinosis/nephrolithiasis (NC/NL) in premature infants 
Study (Year) Design Population and 
Sample Size 
Outcome Measure Results Summary 
Hufnagle (1982)39 Cohort study 10 preterm infants with 
NC 
Renal ultrasound 
(RUS) during NICU 
admission 
All infants received 
furosemide of at least 2 
mg/kg/day for at least 12 
days prior to NC 
Woolfield (1988)40 Cohort study 36 infants with BW ≤ 
1500 grams 
RUS at 12 months of 
age  
3/32 infants had NC on 
ultrasound and these 3 
infants had received chronic 
furosemide with doses 
ranging from 2 to 8 
mg/kg/day. NC resolved in 
2/3 cases; 1 died of 
unrelated causes.  
Jacinto (1988)41  Cohort study 31 infants with BW < 
1500 grams 
RUS in third week of 
life and every 3 week 
thereafter until NICU 
discharge 
 NC was diagnosed in 20/31 
(64%) of infants. Exposure 
to furosemide was more 
common in NC group 
compared to infants without 
NC (65% vs 9.1%; p < 
0.001). NC group had lower 
GA and BW.  
Ezzedeen (1988)42 Cohort study 17 preterm infants with 
NC treated with 
furosemide; 3 preterm 
infants treated with 
furosemide without NC 
(control group) 
RUS during NICU 
admission 
No difference in average 
daily dose or duration of 
furosemide in NC group 
compared to control group.  
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Short (1991)43 Cohort study 79 infants with GA < 32 
weeks 
Serial RUS 21/79 (27%) of infants 
diagnosed with NC. No 
difference in mean total 
dose of furosemide given 
before detection of NC and 
the mean total dose given 
to infants without NC.  
Downing (1991)44 Cohort study 117 infants with BW < 
1750 grams and chronic 
lung disease treated 
with furosemide 
RUS prior to 
discharge and in 3-6 
month intervals for 
positive findings of 
NC/NL  
20/117 (17%) had evidence 
of NC/NL on RUS prior to 
discharge. Infants 
maintained on furosemide 
were more likely to have 
persistent calcifications 
compared to those for 
whom furosemide was 
stopped (p < 0.001). 
Downing (1992)45 Cohort study 27 children born 
prematurely with BW < 
1500 grams enrolled into 
3 groups: 1) Infants not 
exposed to furosemide 
(n=7); 2) Infants who 
received furosemide 
without NC (n=10); and 
3) Infants who received 
furosemide with NC 
(n=10) 
RUS and laboratory 
testing for glomerular 
and tubular kidney 
function 
Infants in group 3 had lower 
creatinine clearance 
(reduced glomerular 
function) and higher tubular 
dysfunction compared to 
infants in group 1 and 2.  
Pope (1996)46 Cohort study 13 preterm infants with 
NC and exposed to 
furosemide divided into 
2 groups: resolution of 
NC (n=6) and persistent 
NC (n=7). 
Serial RUS No difference in duration of 
or cumulative dose of 
furosemide in infants with 
resolution of NC compared 
to those with persistence of 
NC. 
Saarela (1999)47 Cohort study 129 infants with BW < 
1500 grams 
RUS at 2 weeks, 6 
weeks, and 3 months 
of life 
26/129 (20%) of infants 
diagnosed with NC.  The 
mean cumulative doses of 
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furosemide were 
significantly higher in infants 
with NC compared to those 
without NC (18.8 mg vs 5.0 
mg; p < 0.001). 
Schell-Feith (2000)48 Cohort study 215 infants with GA < 32 
weeks 
RUS at 4 weeks of 
life and at term 
NC diagnosed in 50/150 
(33%) of infants at 4 weeks 
of life and 83/201 (41%) at 
term. Furosemide was not 
associated with the 
diagnosis of NC at 4 weeks 
of life. At term, furosemide 
exposure was higher in 
those with NC (32%) 
compared to those without 
NC (18%) (p<0.001).  
Narendra (2001)49 Cohort study 101 infants with GA < 32 
weeks or BW < 1500 
grams 
RUS at 1 month of 
age and at term or 
NICU discharge 
16/101 (16%) diagnosed 
with NC. The median total 
dose of furosemide was not 
significantly different before 
detection of NC on term 
RUS and in infants without 
NC (p = 0.75).  
Hoppe (2002)50 Cohort study 16 infants with GA < 37 
weeks and diagnosed 
with NC 
RUS during NICU 
admission and every 
3-6 months following 
discharge  
NC persisted in 4/12 infants 
who received follow-up. 
Infants with resolution of NC 
received lower dosages of 
furosemide compared to 
those with persistent NC (p 
<0.05). 
Hein (2004)51 Cohort study 114 infants with BW < 
1500 grams divided into 
2 groups: 1) Infants with 
NC (n=20); 2) Infants 
without NC (n=94). 20 
infants from control 
RUS every 2 weeks 
during NICU 
admission 
No difference in duration of 
furosemide therapy 
between infants with NC 
and those without NC. 
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group matched to NC 
group based on BW and 
GA. 
Ketkeaw (2004)52 Cohort study 36 infants with GA < 32 
weeks and BW < 1250 
grams 
RUS prior to NICU 
discharge 
14/36 (39%) were 
diagnosed with NC. The 
mean cumulative dose of 
furosemide was higher in 
infants with NC compared 
to those without NC (102.2 
+/- 118.2 mg vs 32.3 +/- 
81.1 mg; p = 0.001). The 
mean duration of 
furosemide was longer in 
infants with NC compared 
to those without NC (39 vs 
7 days; p = 0.001). NC was 
also associated with 
severity of respiratory 
illness.   
Cranefield (2004)53 Cohort study Cohort of infants 
enrolled in randomized 
trial of two regimens of 
dexamethasone for the 
prevention of chronic 
lung disease. 33 infants 
with BW < 1250 grams 
and on mechanical 
ventilation at 7 days of 
life were enrolled in the 
trial.  
RUS on study entry, 
day of life 28, and at 
discharge or 36 
weeks postmenstrual 
age 
15/18 (83%) of infants for 
whom complete data were 
available were diagnosed 
with NC prior to discharge 
or 36 weeks postmenstrual 
age. Furosemide was used 
infrequently in the trial. 
However, 7/8 of the infants 
who did not receive 
furosemide developed NC. 
Gimpel (2010)54 Cohort study 55 infants with GA < 32 
weeks and BW < 1500 
grams 
RUS obtained after 
the first month of life 
15/55 (27%) of infants were 
diagnosed with NC. The 
strongest independent risk 
factor for NC was 
furosemide therapy with 
cumulative dose > 10 mg/kg 
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(OR 48.1 (95% CI 4.0-585); 
p < 0.01). 
Chang (2011)55 Cohort study 102 infants with GA < 34 
weeks and BW <1500 
grams 
RUS at term or prior 
to NICU discharge 
6/102 (6%) of infants were 
diagnosed with NC. 
Exposure to furosemide 
was more common in the 
NC group compared to the 
group without NC (33% vs 
3%; p = 0.027).  
Lee (2014)56 Cohort study 52 preterm infants with 
BW <1500 grams 
RUS at 4 and 8 
weeks of life 
10/52 infants (19%) were 
diagnosed with NC. 
Exposure to furosemide did 
not differ significantly 
between infants with NC 
and those without NC. 
Mohamed (2014)57 Cohort study 97 infants with GA ≤ 34 
weeks  
RUS at first week of 
life, at term, and at 
one year corrected 
age 
14/97 (14%) infants were 
diagnosed with NC. 
Exposure to furosemide 
was more common in the 
NC group compared to the 
group without NC (50% vs 
15.7%; p = 0.003). 
Abbreviations: BW – Birth weight; GA – Gestational age; OR – Odds ratio; CI – Confidence interval. 
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Table 6: Quality assessment of observational studies examining risk of nephrocalcinosis/nephrolithiasis (NC/NL) in 
premature infants 
Study (Year) Risk of Bias (Low, Moderate, 
Serious, Critical, No 
Information) 
Comments 
Hufnagle (1982)39 Critical Critical risk of bias in confounding domain: 
no statistical tests performed in the 
analysis to test association of NC and 
furosemide. Critical risk of bias in selection 
of participants into the study: All infants 
were exposed to furosemide and had NC; 
lack of control group.  
Woolfield (1988)40 Serious Serious risk of bias in confounding 
domain: no statistical tests performed in 
the analysis to test association of NC and 
furosemide. 
Jacinto (1988)41  Serious Serious risk of bias in confounding 
domain: Lower BW and GA associated 
with outcome (NC), along with exposure to 
furosemide. Did not control for severity of 
illness.  
Ezzedeen (1988)42 Serious Serious risk of bias in confounding 
domain: no adjustment for severity of 
illness; small number of infants in control 
group. 
Short (1991)43 Moderate Multivariate analyses controlling for other 
risk factors for NC. Dose-response 
relationship evaluated. 
Downing (1991)44 Moderate All infants screened for the outcome had a 
diagnosis of chronic lung disease; high 
percentage of follow-up imaging obtained.  
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Downing (1992)45 Moderate Robust comparators; long-term follow-up. 
Pope (1996)46 Moderate Similar severity of illness in each group; 
long-term follow up with serial ultrasounds. 
Dose-response relationship evaluated. 
Saarela (1999)47 Moderate Dose-response relationship evaluated.  
Schell-Feith (2000)48 Moderate Large sample size. Control group without 
NC included. 
Narendra (2001)49 Moderate Multivariate analyses controlling for other 
risk factors for NC. Dose-response 
relationship evaluated. 
Hoppe (2002)50 Serious Serious risk of bias in confounding 
domain: Lack of control group without NC. 
Hein (2004)51 Moderate Large sample size with appropriate control 
groups. 
Ketkeaw (2004)52 Moderate Appropriate control group included. Dose-
response relationship evaluated.  
Cranefield (2004)53 Moderate All infants with comparable severity of 
illness.  
Gimpel (2010)54 Moderate Multivariate analyses controlling for other 
risk factors for NC. Dose-response 
relationship evaluated.  
Chang (2011)55 Serious Serious risk of bias in confounding 
domain: no adjustment for severity of 
illness. Low incidence of NC in sample.  
Lee (2014)56 Serious Serious risk of bias in confounding 
domain: no adjustment for severity of 
illness. 
Mohamed (2014)57 Serious Serious risk of bias in confounding 
domain: no adjustment for severity of 
illness. 
Abbreviations: BW – Birth weight; GA – Gestational age 
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Appendix 
Data Abstraction Form 
Author (Year): 
Reference: 
Eligibility 
1. Was the study originally published in English?   Y/N/Unclear 
2. Did the study use human participants?    Y/N/Unclear 
3. Does the study include premature infants (< 37 weeks GA)? Y/N/Unclear 
4. Were participants exposed to at least one dose of furosemide (enteral or intravenous)? 
         Y/N/Unclear 
5. Does the study examine the risk of hearing loss or nephrocalcinosis/nephrolithiasis in 
premature infants exposed to at least one dose of furosemide? 
         Y/N/Unclear 
Study Characteristics (if eligible) 
1. Study Design:  
2. Sample size: 
3. Gestational age and/or birth weight criteria: 
4. Control group (if applicable): 
5. Outcome(s) examined: 
6. Duration of follow-up: 
7. Summary of results: 
